CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...

New research shows promising signs that the Pfizer and Moderna vaccines might offer protection for a longer time than previously thought. And that protection could potentially last for years Health ...

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public ...

Moderna's full pipeline may fuel long-term growth.

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...